iLite® TLR4 Assay Ready Cells

Add to my product list

iLite® TLR4 Assay Ready Cells are based on a human erythroleukemia cell line  (K562, ATCC# CCL-243) that has been genetically engineered and optimized to respond to stimulus of Toll-like receptor 4 by specific and proportional expression of Firefly Luciferase. Normalization of cell counts and serum matrix effects is obtained by a second reporter gene, a Renilla Luciferase reporter gene construct, under the control of a constitutive promotor.

Product code
Assay Ready Cells

Detection system
Research use only

The iLite® TLR4 Assay Ready Cells can be used for the quantification TLR4 stimulation, and TLR4 inhibitor activity either in buffer systems or in human serum. 
• Quantification of TLR4 stimulation (E-222-GB) 
• Quantification of TLR4 inhibitor activity (E-225-GB) 

The Toll-like receptor (TLR) family, a fundamental part of our immune response, is crucial for triggering innate immunity, and forms the first link to inducing adaptive immunity. TLRs are highly evolutionary conserved across species, from fruit flies to humans. TLR4 is most well-known for recognizing lipopolysaccharide, a component of Gram-negative bacteria, but its ligands also include several viral proteins, polysaccharide, and a variety of endogenous proteins such as low-density lipoprotein, beta-defensins, and heat shock protein (1). 
Activation of TLR4 leads to secretion of a number of proinflammatory cytokines, such TNF-α, IL-1β, IL-6 and Type I IFN. For this reason, a number of TLR4 antagonists are in development for treatment of inflammatory diseases such as inflammatory bowel disease (IBD), rheumatoid arthritis and multiple sclerosis. In contrast to this, TLR4 agonists are explored within oncology, where the immunostimulatory effect of TLR4 is used to enhance the immune response towards tumor cells (2).  

>250 µL of iLite Assay Ready Cells suspended in RPMI 1640 with 20% heat inactivated fetal bovine serum (FBS), mixed 1:1 with cryoprotective medium from Lonza (Cat. No 12-132A).